AstraZeneca plc: Why $4.20 Is The Magic Number

AstraZeneca plc’s (LON: AZN) management will be keeping a keen eye on the company’s earnings.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Executive compensation plans have always drawn shareholders criticism but AstraZeneca’s (LSE: AZN) (NYSE: AZN.US) ‘Azip’ plan has been designed with shareholders in mind. 

Azip was put together in order to safeguard Astra’s dividend payout to investors, as well as encouraging the company’s management to grow the payout at a sustainable rate and grow earnings per share.  

The criteria are simple. In order for the Azip plan to remain in effect, the dividend must not be cut and earnings per share must not fall below 1.5 times the dividend. If either of these targets are not met, then benefits are forfeited. Astra’s CEO, Pascal Soriot, stands to lose a bonus of 89,960 shares, roughly £4.1m worth of stock if the company fails to maintain these standards. 

 So, there’s a lot at stake but why is $4.20 such an important number?

The magic number 

The Azip plan states that Astra’s dividend must be covered one-and-a-half times by earnings per share. For the last three years Astra has paid out a dividend per share of $2.80. Multiply $2.80 by 1.5 and you get $4.20. 

What’s more, as part of the Azip plan, Astra cannot cut the dividend. With this being the case, the payout cannot be lowered in order to maintain cover of one-and-a-half times.

So overall, Astra’s earnings per share must stay above the key $4.20 level. At this level the payout is covered one-and-a-half times and rewards promised under the Azip plan are safe. However, if Astra cuts its dividend to save cash, or the company’s earnings per share fall below $4.20, then awards promised under the Azip plan are forfeit. 

Full steam ahead

Unfortunately, Astra’s management are running out of time to ensure that they meet the Azip criteria. Indeed, as Astra struggles with falling sales of its key products, earnings have been falling over the past five years. Full-year 2013 earnings per share were $5.05, down from $7.28 as reported for full-year 2011.

Moreover, within the group’s recently published third-quarter earnings announcement, management revealed that full-year 2014 earnings would be 15% lower than those reported for 2013, in part because of the stronger dollar. According to my figures, these forecasts suggest that Astra is set to report earnings per share of $4.29 for 2014, only just above the key $4.20 threshold. 

And with that key $4.20 threshold looming, Astra’s management have picked up the pace driving multiple deals through over the past month alone.

For example, since the beginning of October the company has revived the go-ahead from regulators for the development of several new, key drugs. An asset swap with peer Almirall has also been completed and Astra’s global biologics research and development arm, MedImmune, has entered into an agreement to acquire Definiens, a world-leading medical data analysis technology firm. 

Astra’s management knows that they stand to lose a lot if the dividend payout comes under pressure, so they’re working hard to ensure that the company returns to growth.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

How much does an investor need in a Stocks and Shares ISA to earn £1,000 a month in passive income?

A Stocks and Shares ISA's a valuable asset for investors. Not having to pay dividend tax can be a big…

Read more »

Investing Articles

9% dividend yield! Could buying this FTSE 250 stock earn me massive passive income?

Assura looks like an outstanding stock for dividend investors to consider. But is the 9% dividend yield the passive income…

Read more »

Man putting his card into an ATM machine while his son sits in a stroller beside him.
Investing Articles

Why I think this month could be critical for the Lloyds share price!

Our writer explains why he thinks the bank's 2024 results will have a significant impact on the short-term direction of…

Read more »

British Pennies on a Pound Note
Investing Articles

This former penny share has soared 168%. Is the best yet to come?

When Christopher Ruane saw a penny share as a potential bargain last year, he was spot on. So having not…

Read more »

Mature couple at the beach
Investing Articles

£20k in an ISA? Here’s how it could generate £1 of passive income every hour — forever

With a long-term approach, Christopher Ruane explains how an investor could aim to earn a pound per hour in passive…

Read more »

One English pound placed on a graph to represent an economic down turn
Investing Articles

FTSE shares: overpriced or still a bargain?

Christopher Ruane reckons a storming FTSE 100 performance of late doesn't tell us much about whether there are still possible…

Read more »

Blue NIO sports car in Oslo showroom
Investing Articles

Would an investor have made money investing £2k in NIO stock 5 years ago?

Our writer looks at how NIO stock has performed over recent years and weighs the bull and bear cases as…

Read more »

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

5 steps to start buying shares with £5 a day

In a handful of steps, our writer explains how someone new to the stock market could start buying shares for…

Read more »